In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Pretreatment with P2Y12 Receptor Antagonists in ST-Elevation Myocardial Infarction: A Report from the Swedish Coronary Angiography and Angioplasty Registry

Session Comorbidities and cardiomyopathies - How to manage?

Speaker Elmir Omerovic

Event : Heart Failure 2018

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Coronary Artery Disease: Treatment, Revascularization
  • Session type : Rapid Fire Abstracts

Authors : E Omerovic (Gothenburg,SE)

Authors:
E Omerovic1 , 1Sahlgrenska University Hospital - Gothenburg - Sweden ,

Citation:

Background: Prehospital administration of P2Y12 receptor antagonists to patients with ST-elevation myocardial infarction (STEMI) is supported by guidelines and is a common practice despite the lack of definite evidence for its benefit.

Methods: Using data from the Swedish Coronary Angiography and Angioplasty Registry on procedures between 2005 and 2016 we stratified all patients who underwent primary PCI due to STEMI in Sweden by whether or not they were pretreated with P2Y12 receptor antagonists. We investigated associations between P2Y12 pretreatment and the risk of adverse outcomes with propensity-scores adjusted mixed-effects logistic regression, which accounted for clustering of patients within hospitals. The primary endpoint was all-cause death within 30 days. Secondary endpoints were IRA (infarct-related artery) occlusion, 30-day stent thrombosis, in-hospital bleeding, neurological complications and cardiogenic shock.

Results: In total, 44,804 patients were included. They were treated with clopidogrel (N=26,136, 58.3%), ticagrelor (N=15,792, 35.3%), or prasugrel (N=2,352, 5.3%); 37,840 (84.5%) were pretreated, and 30,387 (67.8%) had IRA occlusion. At 30 days, there were 2,488 (5.6%) deaths and 267 (0.6%) stent thromboses. Pretreatment was not associated with better survival (OR 0.1.07; 95% CI 0.94-1.22; P=0.313) at 30 days, reduced IRA occlusion (OR 1.01; 95% CI 0.95-1.08; P=0.635), or decreased stent thrombosis (OR 0.99; 95% CI 0.69-1.41; P=0.941), or higher risk of in-hospital bleeding (OR 1.04; 95% CI 0.89-1.23; P=0.604), or neurological complications (OR 0.66; 95% CI 0.38-1.30; P=0.129). We found no difference in risk of cardiogenic shock between the groups (OR 0.91; 95% CI 0.78 - 1.07; P=0.264)

Conclusion: Pretreatment of STEMI patients with P2Y12 receptor antagonists was not associated with improved clinical outcomes.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are